Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial

Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators

Research output: Contribution to journalArticlepeer-review

264 Citations (Scopus)
Original languageEnglish
Pages (from-to)27-39
Number of pages13
JournalCirculation
Volume132
Issue number1
DOIs
Publication statusPublished - 2015

ASJC Scopus Subject Areas

  • Cardiology and Cardiovascular Medicine
  • Physiology (medical)

Keywords

  • arrhythmias, cardiac
  • calcium
  • death, sudden, cardiac
  • renal insufficiency, chronic
  • ventricular remodeling

Fingerprint

Dive into the research topics of 'Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial'. Together they form a unique fingerprint.

Cite this